RxDoctor Payments DataLook up a doctor →

Erica Kretchman, DO

Endocrinology, Diabetes & Metabolism · Richmond, INNPI 1003013673

Payments from drug & device makers

$636,079in general payments, 2019–2025

Across 1,930 payments — averaging $329.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$227K
  • Lilly USA, LLC$188K
  • Medtronic$51K
  • AstraZeneca$44K
  • Abbott$32K
  • Novo Nordisk AS$28K
  • plus $66K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk316$227,394
Lilly USA, LLC373$187,703
Medtronic(2 entities)89$50,802
AstraZeneca(2 entities)122$44,214
Abbott79$32,448
Novo Nordisk AS15$27,515
Boehringer Ingelheim97$25,573
Valeritas, Inc.71$18,781
Mannkind Corporation55$5,426
Dexcom, Inc.32$4,127
Zealand Pharma US, Inc.74$2,634
Amgen(2 entities)142$1,661
Corcept Therapeutics91$1,468
Sanofi-aventis U.S. LLC63$902
Xeris Pharmaceuticals, Inc.33$582
Bayer36$578
Tandem Diabetes Care, Inc.32$522
Insulet Corporation26$432
Recordati_rare_diseases_inc.22$391
Amarin Pharma, Inc.21$330
Merck16$242
IBSA Pharma Inc.12$221
Ascendis Pharma Endocrinology Inc5$189
Cequr Corporation3$185
Novartis9$179
Radius Health, Inc.10$161
AbbVie9$146
Shire North American Group Inc8$113
Ascensia Diabetes Care US Inc.4$102
Madrigal Pharmaceuticals3$99
Esperion Therapeutics, Inc.7$95
Lifescan, Inc.6$75
Neurocrine Biosciences, Inc.3$72
Ultragenyx Pharmaceutical Inc.3$62
Sequel Med Tech, LLC3$52
Johnson & Johnson4$49
Amryt Pharma Holdings Ltd3$46
Pfizer3$46
Regeneron Healthcare Solutions, Inc.3$44
Companion Medical, Inc.3$41
Averitas Pharma Inc.2$38
Currax Pharmaceuticals LLC3$37
Ipsen Biopharmaceuticals, Inc2$36
Lexicon Pharmaceuticals, Inc.2$34
Renalytix AI, Inc.2$27
Alvogen Inc1$23
RGH Enterprises LLC1$23
Clarus Therapeutics Inc.2$20
EUSA Pharma (US) LLC1$20
BETA Bionics, Inc.1$20
Antares Pharma, Inc.1$18
Senseonics, Incorporated1$16
Evoke Pharma, Inc.1$16
Eisai Inc.1$15
Acerus Pharmaceuticals Corporation1$14
Tolmar Pharmaceuticals, Inc.1$13
Kowa Pharmaceuticals America, Inc.1$11

How this compares

$636,079 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana →

Medicare billing

Part B allowed, 2024
$163,979
Medicare patients
804
Services billed
3,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Richmond

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →